InsiderTrades.com logo
Patrick D. Yeramian net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Patrick Yeramian Biography and Net Worth

Insider of Amylyx Pharmaceuticals
Patrick Yeramian is the Insider of Amylyx Pharmaceuticals.

What is Patrick D. Yeramian's net worth?

The estimated net worth of Patrick D. Yeramian is at least $2.98 million as of January 9th, 2024. Yeramian owns 205,605 shares of Amylyx Pharmaceuticals stock worth more than $2,979,216 as of December 5th. This net worth approximation does not reflect any other assets that Yeramian may own. Learn More about Patrick D. Yeramian's net worth.

How do I contact Patrick D. Yeramian?

The corporate mailing address for Yeramian and other Amylyx Pharmaceuticals executives is , , . Amylyx Pharmaceuticals can also be reached via phone at 617-682-0917 and via email at [email protected]. Learn More on Patrick D. Yeramian's contact information.

Has Patrick D. Yeramian been buying or selling shares of Amylyx Pharmaceuticals?

Patrick D. Yeramian has not been actively trading shares of Amylyx Pharmaceuticals during the last ninety days. Most recently, Patrick D. Yeramian sold 2,812 shares of the business's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $16.33, for a transaction totalling $45,919.96. Following the completion of the sale, the insider now directly owns 205,605 shares of the company's stock, valued at $3,357,529.65. Learn More on Patrick D. Yeramian's trading history.

Who are Amylyx Pharmaceuticals' active insiders?

Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amylyx Pharmaceuticals?

In the last year, Amylyx Pharmaceuticals insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $37,000.00. In the last year, insiders at the sold shares 13 times. They sold a total of 169,893 shares worth more than $1,666,686.16. The most recent insider tranaction occured on December, 1st when insider Camille L Bedrosian sold 6,580 shares worth more than $94,423.00. Insiders at Amylyx Pharmaceuticals own 12.3% of the company. Learn More about insider trades at Amylyx Pharmaceuticals.

Information on this page was last updated on 12/1/2025.

Patrick D. Yeramian Insider Trading History at Amylyx Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2024Sell2,812$16.33$45,919.96205,605View SEC Filing Icon  
5/15/2023Sell11,965$29.03$347,343.95208,417View SEC Filing Icon  
4/17/2023Sell49,579$30.54$1,514,142.66208,417View SEC Filing Icon  
3/16/2023Sell54,627$31.87$1,740,962.49149,672View SEC Filing Icon  
See Full Table

Patrick D. Yeramian Buying and Selling Activity at Amylyx Pharmaceuticals

This chart shows Patrick D Yeramian's buying and selling at Amylyx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amylyx Pharmaceuticals Company Overview

Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $14.49
Low: $13.91
High: $14.64

50 Day Range

MA: $14.00
Low: $12.18
High: $15.79

2 Week Range

Now: $14.49
Low: $2.60
High: $16.96

Volume

781,740 shs

Average Volume

1,403,731 shs

Market Capitalization

$1.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A